1338705-65-9

Upstream product

• 1338705-62-6 C₂₇H₂₄ClNO₈ 
• 1338705-63-7 2-chloro-3,4-bis((4-methoxybenzyl)oxy)benzohydrazide 
• 1338705-64-8 2-chloro-N'-(2-chloroacetyl)-3,4-bis((4-methoxybenzyl)oxy)benzohydrazide 
• 52009-53-7 2-chloro-3,4-dimethoxy-benzoic acid 
• 5417-17-4 2-chloro-3,4-dimethoxybenzaldehyde 
• 1338705-74-0 C₂₄H₂₃ClO₆ 

Downstream Products

• 1338705-66-0 2-(2-chloro-3,4-bis((4-methoxybenzyl)oxy)phenyl)-5-(pyrrolidin-1-ylmethyl)-1,3,4-oxadiazole 

Relevant academic research and scientific papers

Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship

The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection.

CEPHEM COMPOUND HAVING CATECHOL GROUP

A compound of the formula: wherein X is -N=, -CH=, or the like; W is -CH2- or the like; U is -S- or the like; R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; R3/su